Galakatos says 'the most important current breakthrough in science is our increasing ability to practise precision medicine based on our understanding of the human genome'.
The private equity firm took pharma services company Ergomed private in November.
‘There is a lot of pipeline, but it takes time for LPs to get comfortable with a new strategy,’ says CEO Laurent Benard.
'The cool thing about collaborations is that they don’t have to be right on point,' says Tom Pitts, head of Europe for LionRock.
The private equity firm will help the decision-support software and data science company bolster its product offering via acquisitions, says partner Zak Ewen.
Public-to-privates, family-backed businesses managing generational change and debt-for-control opportunities will also be in vogue, says Triton's Claus von Hermann.
'Many of the largest co-investment LPs were less active in 2023, leading to strong dealflow for smaller-and mid-sized LPs with co-invest programmes,' says Verdane partner Frida Einarson.
Bluegem’s sale of Dr Vranjes Firenze relied on ‘a process tailored to trade buyers who are less affected by the expensive financing’, says founding partner Emilio Di Spiezio Sardo.
‘It’s an exciting time in the real estate industry and there’s a lot of disruptive change,’ says Pictet's Edmund Buckley.
The private equity firm aims to grow the Swedish biotech company’s footprint in the US, partner Isabel de Paoli told PE Hub Europe.